Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.48 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylglutamic Acid SCHEMBL716411 | 0.83 | FOLH1 (0.69) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| Acetylglutamic Acid SCHEMBL82128 | 0.83 | FOLH1 (0.69) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| Aceglumate SCHEMBL198970 | 0.83 | FOLH1 (0.69) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| Acetylglutamic Acid SCHEMBL2512801 | 0.83 | FOLH1 (0.69) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL11885251 | 0.83 | MAPT (0.57) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL14557466 | 0.83 | MAPT (0.57) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL17715158 | 0.82 | MAPT (0.52) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL4577285 | 0.82 | MAPT (0.52) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| Acetylglutamic Acid SCHEMBL11403044 | 0.82 | FOLH1 (0.67) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| Aceglumate SCHEMBL11403040 | 0.82 | FOLH1 (0.67) | SMN1; SMN2MAPTKDM4ETHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-04-28 | — | — | US | disclosed |
| US-7910568-B2 | Inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, gastrointestinal disorders; prevention/treatment of colon cancer; releases hydrogen sulfide | ANTIBE THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | SMN1; SMN2 4347/4885MAPT 3407/4885KDM4E 739/4885 |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | SMN1; SMN2 4347/4885MAPT 3407/4885KDM4E 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.